Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy - Full Text View

Sponsored by:	Texas A&M University
Information provided by:	Texas A&M University
ClinicalTrials.gov Identifier:	NCT00260442

Purpose

The purpose of this study is to examine the effect of dietary cholesterol administered as whole egg or egg white (control)on muscle mass gain with resistance training in a young old population of men and women (age 50-69). It is hypothesized that dietary cholesterol will be significantly associated to muscle mass gain.

Condition	Intervention	Phase
Sarcopenia Cardiovascular Disease	Behavioral: resistance training with dietary cholesterol administration	Phase II

MedlinePlus related topics: Cholesterol

Drug Information available for: Cholest-5-en-3-ol (3beta)- Lipids

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy

Further study details as provided by Texas A&M University:

Primary Outcome Measures:

Primary: Strength and muscle gain (DEXA) after 12 weeks of resistance training

Secondary Outcome Measures:

Secondary: Blood lipids, inflammatory markers, blood pressure after 12 weeks of resistance training

Estimated Enrollment:	36
Study Start Date:	November 2005
Estimated Study Completion Date:	April 2007

Detailed Description:

The primary objective of this proposal is to have 36 men and women (age 50-69) perform 12 weeks of resistance exercise training for the purpose of inducing skeletal muscle hypertrophy. These individuals will consume either 0, 1, or 3 whole eggs per day in a double-blind design to test the hypothesis that dietary cholesterol is essential for skeletal muscle hypertrophy. If so proven, this will confirm a very strong association between dietary cholesterol and hypertrophy observed in a previous study of 51 men and women (age 60-69). The current proposal is using a randomized double-blind, placebo controlled design to provide the most conclusive evidence that dietary cholesterol plays an essential role in skeletal muscle hypertrophy.

The secondary objective of this proposal is to test the hypothesis that increased dietary cholesterol consumption in the context of an exercise program does not alter blood cholesterol concentrations or other cardiovascular risk factors.

Eligibility

Ages Eligible for Study:	50 Years to 69 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

men and women aged 50-69
able to perform exercise testing and training

Exclusion Criteria:

blood pressure > 160/100
cardiac arrhythmias
cancer
hernia
aortic aneurysm
kidney disease
lung disease
total cholesterol > 240 mg/dl or < 160 mg/dl
current use of cholesterol lowering medications
actively participating in >1 hour per week of resistance training

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260442

Contacts

Contact: Steven E Riechman, PhD, MPH	979-862-3213	sriechman@hlkn.tamu.edu
Contact: Heath Gasier, MS, RD	979-845-5390	hgasier@neo.tamu.edu

Locations

United States, Texas
Texas A&M University	Recruiting
College Station, Texas, United States, 77843
Principal Investigator: Steven E Riechman, PhD, MPH

Sponsors and Collaborators

Texas A&M University

Investigators

Principal Investigator:

Steven E Riechman, PhD, MPH

Texas A&M University

More Information

Study ID Numbers:	06-0187, 481031-001-CA, 0600083
Study First Received:	November 29, 2005
Last Updated:	April 18, 2007
ClinicalTrials.gov Identifier:	NCT00260442
Health Authority:	United States: Institutional Review Board

Keywords provided by Texas A&M University:

sarcopenia
resistance training
strength training
skeletal muscle
elderly
cholesterol

aging
cardiovascular disease
nutrition
inflammation
lipids

Study placed in the following topic categories:

Pathological Conditions, Anatomical
Hypertrophy
Inflammation

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009